Informations générales (source: ClinicalTrials.gov)
                                    Influence of the PEPA Membrane on the Undernutrition Syndrome Inflammation in Chronic Hemodialysis
                                
                            
                                    Interventional
                                
                            
                                    N/A
                                
                            
                                    Theradial (Voir sur ClinicalTrials)
                                
                            
                                    juillet 2011
                                
                            
                                    décembre 2021
                                
                            
                                    18 septembre 2025
                                
                            
                                    NutriPEPA2 is a randomized, single-blind, prospective, multicenter trial, in two parallel
arms to confirm that the adsorbent PEPA membrane may decrease mortality related to
inflammation and malnutrition encountered in HD or HDF-treated stage 5 renal failure
compared to a non-adsorbent synthetic membrane.
                                
                            Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AURA PARIS PLAISANCE | Pascal SERIS, Doctor | Contact (sur clinicalTrials) | |||
| EFS IDF SITE MEAUX | Hala MOURAM, Doctor | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Ch Annonay - 07103 - Annonay - France | Vincent BISSACCIA, Doctor | Contact (sur clinicalTrials) | |||
| Ch Metz-Thionville - 57085 - Metz - France | Zead TUBAIL, Doctor | Contact (sur clinicalTrials) | |||
| CH Saint Brieuc - 22027 - Saint-Brieuc - France | Rehouni BOULAHROUZ, Doctor | Contact (sur clinicalTrials) | |||
| CH Saint Quentin - 02321 - Saint-Quentin - France | Mahen AL BADAWY, Doctor | Contact (sur clinicalTrials) | |||
| Chru Tours - 37044 - Tours - France | Maud FRANCOIS, Doctor | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Ch Besancon - 25030 - Besançon - France | Maria YANNARAKI, Doctor | Contact (sur clinicalTrials) | |||
| Ch Chartres - 28018 - Chartres - France | Catherine ALBERT, Doctor | Contact (sur clinicalTrials) | |||
| Ch La Rochelle - 17019 - La Rochelle - France | Francois POURREAU, Doctor | Contact (sur clinicalTrials) | |||
| Ch Toulouse Larrey - 31400 - Toulouse - France | Arnaud DEL BELLO, Doctor | Contact (sur clinicalTrials) | |||
Critères
                                    Tous
                                
                            
                                    Inclusion Criteria:
- Patient with Chronic Renal Insufficiency Stage 5, treated by fistula or permanent
catheters,
- Medium albumin (on 3 recent assays) of less than 35 g / l (this assay being carried
out by a non-electrophoretic technique),
- PINI score greater than or equal to 1,
- Beginning of the treatment of extra-renal purification by hemodialysis for at least
3 months on a non-adsorbing synthetic membrane (of the Polysulfone,
Polyethersulfone, PolyArylethersulfone type) of surface at least equal to that of
the PEPA dialyser
                                
                            - Patient with Chronic Renal Insufficiency Stage 5, treated by fistula or permanent
catheters,
- Medium albumin (on 3 recent assays) of less than 35 g / l (this assay being carried
out by a non-electrophoretic technique),
- PINI score greater than or equal to 1,
- Beginning of the treatment of extra-renal purification by hemodialysis for at least
3 months on a non-adsorbing synthetic membrane (of the Polysulfone,
Polyethersulfone, PolyArylethersulfone type) of surface at least equal to that of
the PEPA dialyser
- Patients allergic to PEPA,
- Patients with insufficient vascular access,
- Patients with digestive syndromes: Hepatopathy, gastrointestinal amyloidosis,
chronic diarrhea, myeloma and dysglobulinaemia, neoplasia and hematopathy, a serious
illness that is life-threatening in the short term,